Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical Progression in Patients with Metastatic Hormone-Sensitive Prostate Cancer By Ogkologos - May 27, 2025 321 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a post-hoc analysis of the ENZAMET study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Studying “Total Diet” and Its Impact on Health, Including Cancer Risk October 25, 2018 Doctors Think Woman Has A Brain Tumor, But Then They Open... June 17, 2019 Extended Follow-Up Further Supports Lenvatinib Plus Pembrolizumab in Patients with Previously... April 20, 2023 ΠΩΣ ΠΡΟΚΑΛΕΙΤΑΙ January 18, 2019 Load more HOT NEWS Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent... New on NCI’s Websites for October 2019 Neoadjuvant Pembrolizumab Associated with Limited Side Effects and High Clinical Activity... Daratumumab Plus Bortezomib and Dexamethasone Regimen Significantly Prolongs OS in Patients...
